Cite
MLA Citation
R. Shapira-Frommer et al.. “2746 A Phase 2 open-label, multicenter study of single-agent rucaparib in the treatment of patients with relapsed ovarian cancer and a deleterious BRCA mutation.” European journal of cancer, vol. 51, n.d., pp. S545–. http://access.bl.uk/ark:/81055/vdc_100030628262.0x000017